314 related articles for article (PubMed ID: 30443191)
1. PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis.
Wang Y; Hao F; Nan Y; Qu L; Na W; Jia C; Chen X
Int J Biol Sci; 2018; 14(13):1883-1891. PubMed ID: 30443191
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin.
Wang X; Zhang F; Wu XR
Sci Rep; 2017 Apr; 7():45983. PubMed ID: 28378811
[TBL] [Abstract][Full Text] [Related]
3. Antitumor Effect of Shikonin, a PKM2 Inhibitor, in Cholangiocarcinoma Cell Lines.
Thonsri U; Seubwai W; Waraasawapati S; Wongkham S; Boonmars T; Cha'on U; Wongkham C
Anticancer Res; 2020 Sep; 40(9):5115-5124. PubMed ID: 32878800
[TBL] [Abstract][Full Text] [Related]
4. PKM2 inhibitor shikonin suppresses TPA-induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells.
Li W; Liu J; Zhao Y
Mol Carcinog; 2014 May; 53(5):403-12. PubMed ID: 23255458
[TBL] [Abstract][Full Text] [Related]
5. Shikonin differentially regulates glucose metabolism via PKM2 and HIF1α to overcome apoptosis in a refractory HCC cell line.
Yang W; Liu J; Hou L; Chen Q; Liu Y
Life Sci; 2021 Jan; 265():118796. PubMed ID: 33220292
[TBL] [Abstract][Full Text] [Related]
6. Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway.
Dai Y; Liu Y; Li J; Jin M; Yang H; Huang G
Bioengineered; 2022 May; 13(5):13906-13918. PubMed ID: 35706397
[TBL] [Abstract][Full Text] [Related]
7. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.
Mizutani Y; Nakao M; Ogawa O; Yoshida O; Bonavida B; Miki T
J Urol; 2001 Jan; 165(1):263-70. PubMed ID: 11125422
[TBL] [Abstract][Full Text] [Related]
8. Tumor M2-PK: A novel urine marker of bladder cancer.
Liu W; Woolbright BL; Pirani K; Didde R; Abbott E; Kaushik G; Martin P; Hamilton-Reeves J; Taylor JA; Holzbeierlein JM; Anant S; Lee EK
PLoS One; 2019; 14(6):e0218737. PubMed ID: 31246990
[TBL] [Abstract][Full Text] [Related]
9. Shikonin Suppresses Skin Carcinogenesis via Inhibiting Cell Proliferation.
Li W; Zhang C; Ren A; Li T; Jin R; Li G; Gu X; Shi R; Zhao Y
PLoS One; 2015; 10(5):e0126459. PubMed ID: 25961580
[TBL] [Abstract][Full Text] [Related]
10. Necroptosis inhibits autophagy by regulating the formation of RIP3/p62/Keap1 complex in shikonin-induced ROS dependent cell death of human bladder cancer.
Liu X; Liu L; Wang X; Jin Y; Wang S; Xie Q; Jin Y; Zhang M; Liu Y; Li J; Wang Z; Fu X; Jin CY
Phytomedicine; 2023 Sep; 118():154943. PubMed ID: 37421765
[TBL] [Abstract][Full Text] [Related]
11. Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines.
Kim SH; Ho JN; Jin H; Lee SC; Lee SE; Hong SK; Lee JW; Lee ES; Byun SS
Investig Clin Urol; 2016 Jan; 57(1):63-72. PubMed ID: 26966728
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of PKM2 decreases FASN expression in bladder cancer cells through AKT/mTOR/SREBP-1c axis.
Tao T; Su Q; Xu S; Deng J; Zhou S; Zhuang Y; Huang Y; He C; He S; Peng M; Hocher B; Yang X
J Cell Physiol; 2019 Mar; 234(3):3088-3104. PubMed ID: 30221356
[TBL] [Abstract][Full Text] [Related]
13. The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis.
Fu Z; Deng B; Liao Y; Shan L; Yin F; Wang Z; Zeng H; Zuo D; Hua Y; Cai Z
BMC Cancer; 2013 Dec; 13():580. PubMed ID: 24314238
[TBL] [Abstract][Full Text] [Related]
14. RIP1K and RIP3K provoked by shikonin induce cell cycle arrest in the triple negative breast cancer cell line, MDA-MB-468: necroptosis as a desperate programmed suicide pathway.
Shahsavari Z; Karami-Tehrani F; Salami S; Ghasemzadeh M
Tumour Biol; 2016 Apr; 37(4):4479-91. PubMed ID: 26496737
[TBL] [Abstract][Full Text] [Related]
15. Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway.
Tang JC; Ren YG; Zhao J; Long F; Chen JY; Jiang Z
Life Sci; 2018 Jul; 204():71-77. PubMed ID: 29738778
[TBL] [Abstract][Full Text] [Related]
16. Shikonin-induced apoptosis involves caspase-3 activity in a human bladder cancer cell line (T24).
Yeh CC; Kuo HM; Li TM; Lin JP; Yu FS; Lu HF; Chung JG; Yang JS
In Vivo; 2007; 21(6):1011-9. PubMed ID: 18210748
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells.
Cho HJ; Kim JK; Kim KD; Yoon HK; Cho MY; Park YP; Jeon JH; Lee ES; Byun SS; Lim HM; Song EY; Lim JS; Yoon DY; Lee HG; Choe YK
Cancer Lett; 2006 Jun; 237(1):56-66. PubMed ID: 16009487
[TBL] [Abstract][Full Text] [Related]
18. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2.
Chen J; Xie J; Jiang Z; Wang B; Wang Y; Hu X
Oncogene; 2011 Oct; 30(42):4297-306. PubMed ID: 21516121
[TBL] [Abstract][Full Text] [Related]
19. Shikonin kills glioma cells through necroptosis mediated by RIP-1.
Huang C; Luo Y; Zhao J; Yang F; Zhao H; Fan W; Ge P
PLoS One; 2013; 8(6):e66326. PubMed ID: 23840441
[TBL] [Abstract][Full Text] [Related]
20. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG
Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
